Oncology
WOCKHARDT CONTINUES TO SUPPLY A HEALTHY ONCOLOGY PRODUCT PIPELINE IN THE UK.
The following information is intended for healthcare professionals
Oncology is a key focus area for our business. Wockhardt UK has
a broad cancer care portfolio, including:
- Cytotoxic drugs
- Opioid analgesics
- Heparin flushes
- Disodium pamidronate
- Hyaluronidase
- Tamoxifen
Furthermore, we plan to significantly expand our oncology range
through:
- Established Marketing Partnerships
Wockhardt UK has developed strategic marketing partnerships with
key European manufacturing specialists. Producing a wide range
of oncology products and specialising in ready-to-use injectable
solutions, our partner companies work alongside us to expand our oncology range and bring generic cancer care products to the UK market. With many years
of production experience and manufacturing plants that meet EU and FDA requirements,
investment continues year on year to ensure compliance with
the highest quality assurance standards.
- New Product Development
Wockhardt continues to invest heavily in expanding its oncology range through new product development,
providing a healthy product pipeline for our UK Oncology
business. Our parent company’s world class Research & Development
facility supports a multidisciplinary programme involving
biotechnology, super-generics and new chemical entities.
Innovation drives growth - so look out for new additions to our
Oncology range.
For a full Oncology product listing, please select the Oncology Therapy
Area within the Product Search function. |
